CD Private Equity Fund III
Get $10 bonus on your first $100 deposit for CD3.AX
Get $10 bonus on your first $100 deposit for CD3.AX
CD Private Equity Fund III (CD3.AX) Stock Competitors & Peer Comparison
See (CD3.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Asset Management Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CD3.AX | A$0.92 | +2.23% | 65.9M | 3.98 | A$0.23 | +15.30% |
| SPY.AX | A$968.75 | +1.10% | 972.3B | 7.59 | A$127.65 | +1.08% |
| VAS.AX | A$111.04 | +0.60% | 23.3B | 21.84 | A$5.08 | +3.08% |
| IVV.AX | A$64.70 | +1.11% | 12.7B | 27.33 | A$2.37 | +1.05% |
| VGS.AX | A$146.80 | +1.06% | 12.3B | 24.64 | A$5.96 | +1.71% |
| A200.AX | A$149.98 | +0.64% | 9.2B | 21.94 | A$6.83 | +3.30% |
| VTS.AX | A$478.39 | +1.25% | 8.8B | N/A | N/A | +1.05% |
| AFI.AX | A$6.74 | +0.90% | 8.4B | 30.64 | A$0.22 | +5.04% |
| IOZ.AX | A$36.02 | +0.59% | 8.2B | 21.25 | A$1.70 | +3.46% |
| NDQ.AX | A$52.89 | +1.40% | 8B | 33.58 | A$1.57 | +0.98% |
Stock Comparison
CD3.AX vs SPY.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, SPY.AX has a market cap of 972.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while SPY.AX trades at A$968.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas SPY.AX's P/E ratio is 7.59. In terms of profitability, CD3.AX's ROE is +0.13%, compared to SPY.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to SPY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check SPY.AX's competition here
CD3.AX vs VAS.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VAS.AX has a market cap of 23.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VAS.AX trades at A$111.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VAS.AX's P/E ratio is 21.84. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VAS.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VAS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VAS.AX's competition here
CD3.AX vs IVV.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IVV.AX has a market cap of 12.7B. Regarding current trading prices, CD3.AX is priced at A$0.92, while IVV.AX trades at A$64.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IVV.AX's P/E ratio is 27.33. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IVV.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to IVV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IVV.AX's competition here
CD3.AX vs VGS.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VGS.AX has a market cap of 12.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VGS.AX trades at A$146.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VGS.AX's P/E ratio is 24.64. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VGS.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VGS.AX's competition here
CD3.AX vs A200.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, A200.AX has a market cap of 9.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while A200.AX trades at A$149.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas A200.AX's P/E ratio is 21.94. In terms of profitability, CD3.AX's ROE is +0.13%, compared to A200.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to A200.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check A200.AX's competition here
CD3.AX vs VTS.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VTS.AX has a market cap of 8.8B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VTS.AX trades at A$478.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VTS.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VTS.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VTS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VTS.AX's competition here
CD3.AX vs AFI.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, AFI.AX has a market cap of 8.4B. Regarding current trading prices, CD3.AX is priced at A$0.92, while AFI.AX trades at A$6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas AFI.AX's P/E ratio is 30.64. In terms of profitability, CD3.AX's ROE is +0.13%, compared to AFI.AX's ROE of +0.03%. Regarding short-term risk, CD3.AX is less volatile compared to AFI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check AFI.AX's competition here
CD3.AX vs IOZ.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IOZ.AX has a market cap of 8.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while IOZ.AX trades at A$36.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IOZ.AX's P/E ratio is 21.25. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IOZ.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to IOZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IOZ.AX's competition here
CD3.AX vs NDQ.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, NDQ.AX has a market cap of 8B. Regarding current trading prices, CD3.AX is priced at A$0.92, while NDQ.AX trades at A$52.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas NDQ.AX's P/E ratio is 33.58. In terms of profitability, CD3.AX's ROE is +0.13%, compared to NDQ.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to NDQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check NDQ.AX's competition here
CD3.AX vs QUAL.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, QUAL.AX has a market cap of 7.8B. Regarding current trading prices, CD3.AX is priced at A$0.92, while QUAL.AX trades at A$59.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas QUAL.AX's P/E ratio is 27.42. In terms of profitability, CD3.AX's ROE is +0.13%, compared to QUAL.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to QUAL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check QUAL.AX's competition here
CD3.AX vs VEU.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VEU.AX has a market cap of 7.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VEU.AX trades at A$112.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VEU.AX's P/E ratio is 4.48. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VEU.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VEU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VEU.AX's competition here
CD3.AX vs VHY.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VHY.AX has a market cap of 7B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VHY.AX trades at A$85.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VHY.AX's P/E ratio is 21.02. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VHY.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VHY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VHY.AX's competition here
CD3.AX vs ARG.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, ARG.AX has a market cap of 6.7B. Regarding current trading prices, CD3.AX is priced at A$0.92, while ARG.AX trades at A$8.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas ARG.AX's P/E ratio is 25.17. In terms of profitability, CD3.AX's ROE is +0.13%, compared to ARG.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is less volatile compared to ARG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check ARG.AX's competition here
CD3.AX vs VGAD.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VGAD.AX has a market cap of 6.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VGAD.AX trades at A$121.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VGAD.AX's P/E ratio is 24.85. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VGAD.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VGAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VGAD.AX's competition here
CD3.AX vs STW.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, STW.AX has a market cap of 6.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while STW.AX trades at A$80.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas STW.AX's P/E ratio is 21.47. In terms of profitability, CD3.AX's ROE is +0.13%, compared to STW.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to STW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check STW.AX's competition here
CD3.AX vs AAA.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, AAA.AX has a market cap of 5.1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while AAA.AX trades at A$50.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas AAA.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to AAA.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to AAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check AAA.AX's competition here
CD3.AX vs GQG.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, GQG.AX has a market cap of 5.1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while GQG.AX trades at A$1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas GQG.AX's P/E ratio is 7.39. In terms of profitability, CD3.AX's ROE is +0.13%, compared to GQG.AX's ROE of +1.08%. Regarding short-term risk, CD3.AX is less volatile compared to GQG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check GQG.AX's competition here
CD3.AX vs JHG.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, JHG.AX has a market cap of 4.9B. Regarding current trading prices, CD3.AX is priced at A$0.92, while JHG.AX trades at A$39.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas JHG.AX's P/E ratio is 12.86. In terms of profitability, CD3.AX's ROE is +0.13%, compared to JHG.AX's ROE of +0.08%. Regarding short-term risk, CD3.AX is less volatile compared to JHG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check JHG.AX's competition here
CD3.AX vs VDHG.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VDHG.AX has a market cap of 3.6B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VDHG.AX trades at A$73.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VDHG.AX's P/E ratio is 22.13. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VDHG.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to VDHG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VDHG.AX's competition here
CD3.AX vs AMP.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, AMP.AX has a market cap of 3.5B. Regarding current trading prices, CD3.AX is priced at A$0.92, while AMP.AX trades at A$1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas AMP.AX's P/E ratio is 27.80. In terms of profitability, CD3.AX's ROE is +0.13%, compared to AMP.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is less volatile compared to AMP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check AMP.AX's competition here
CD3.AX vs VAF.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VAF.AX has a market cap of 3.4B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VAF.AX trades at A$45.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VAF.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VAF.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to VAF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VAF.AX's competition here
CD3.AX vs IHVV.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IHVV.AX has a market cap of 3.4B. Regarding current trading prices, CD3.AX is priced at A$0.92, while IHVV.AX trades at A$62.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IHVV.AX's P/E ratio is 27.05. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IHVV.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to IHVV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IHVV.AX's competition here
CD3.AX vs PNI.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, PNI.AX has a market cap of 3.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while PNI.AX trades at A$14.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas PNI.AX's P/E ratio is 26.18. In terms of profitability, CD3.AX's ROE is +0.13%, compared to PNI.AX's ROE of +0.14%. Regarding short-term risk, CD3.AX is less volatile compared to PNI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check PNI.AX's competition here
CD3.AX vs IFL.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IFL.AX has a market cap of 3.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while IFL.AX trades at A$4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IFL.AX's P/E ratio is 28.18. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IFL.AX's ROE of +0.05%. Regarding short-term risk, CD3.AX is less volatile compared to IFL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IFL.AX's competition here
CD3.AX vs MVW.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, MVW.AX has a market cap of 3.1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while MVW.AX trades at A$38.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas MVW.AX's P/E ratio is 16.30. In terms of profitability, CD3.AX's ROE is +0.13%, compared to MVW.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to MVW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MVW.AX's competition here
CD3.AX vs VAP.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VAP.AX has a market cap of 2.8B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VAP.AX trades at A$87.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VAP.AX's P/E ratio is 14.77. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VAP.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VAP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VAP.AX's competition here
CD3.AX vs MFF.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, MFF.AX has a market cap of 2.8B. Regarding current trading prices, CD3.AX is priced at A$0.92, while MFF.AX trades at A$4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas MFF.AX's P/E ratio is 10.68. In terms of profitability, CD3.AX's ROE is +0.13%, compared to MFF.AX's ROE of +0.18%. Regarding short-term risk, CD3.AX is less volatile compared to MFF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MFF.AX's competition here
CD3.AX vs HBRD.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, HBRD.AX has a market cap of 2.5B. Regarding current trading prices, CD3.AX is priced at A$0.92, while HBRD.AX trades at A$10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas HBRD.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to HBRD.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to HBRD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check HBRD.AX's competition here
CD3.AX vs QHAL.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, QHAL.AX has a market cap of 2.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while QHAL.AX trades at A$53.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas QHAL.AX's P/E ratio is 28.20. In terms of profitability, CD3.AX's ROE is +0.13%, compared to QHAL.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to QHAL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check QHAL.AX's competition here
CD3.AX vs QPON.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, QPON.AX has a market cap of 1.9B. Regarding current trading prices, CD3.AX is priced at A$0.92, while QPON.AX trades at A$26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas QPON.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to QPON.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to QPON.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check QPON.AX's competition here
CD3.AX vs WAM.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, WAM.AX has a market cap of 1.9B. Regarding current trading prices, CD3.AX is priced at A$0.92, while WAM.AX trades at A$1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas WAM.AX's P/E ratio is 21.50. In terms of profitability, CD3.AX's ROE is +0.13%, compared to WAM.AX's ROE of +0.05%. Regarding short-term risk, CD3.AX is less volatile compared to WAM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check WAM.AX's competition here
CD3.AX vs WLE.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, WLE.AX has a market cap of 1.9B. Regarding current trading prices, CD3.AX is priced at A$0.92, while WLE.AX trades at A$1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas WLE.AX's P/E ratio is 15.56. In terms of profitability, CD3.AX's ROE is +0.13%, compared to WLE.AX's ROE of +0.07%. Regarding short-term risk, CD3.AX is less volatile compared to WLE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check WLE.AX's competition here
CD3.AX vs PPT.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, PPT.AX has a market cap of 1.9B. Regarding current trading prices, CD3.AX is priced at A$0.92, while PPT.AX trades at A$16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas PPT.AX's P/E ratio is -100.31. In terms of profitability, CD3.AX's ROE is +0.13%, compared to PPT.AX's ROE of -0.01%. Regarding short-term risk, CD3.AX is less volatile compared to PPT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check PPT.AX's competition here
CD3.AX vs PMGOLD.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, PMGOLD.AX has a market cap of 1.8B. Regarding current trading prices, CD3.AX is priced at A$0.92, while PMGOLD.AX trades at A$66.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas PMGOLD.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to PMGOLD.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to PMGOLD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check PMGOLD.AX's competition here
CD3.AX vs VGE.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VGE.AX has a market cap of 1.8B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VGE.AX trades at A$89.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VGE.AX's P/E ratio is 15.51. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VGE.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VGE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VGE.AX's competition here
CD3.AX vs MFG.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, MFG.AX has a market cap of 1.7B. Regarding current trading prices, CD3.AX is priced at A$0.92, while MFG.AX trades at A$9.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas MFG.AX's P/E ratio is 11.56. In terms of profitability, CD3.AX's ROE is +0.13%, compared to MFG.AX's ROE of +0.14%. Regarding short-term risk, CD3.AX is less volatile compared to MFG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MFG.AX's competition here
CD3.AX vs GDG.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, GDG.AX has a market cap of 1.7B. Regarding current trading prices, CD3.AX is priced at A$0.92, while GDG.AX trades at A$4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas GDG.AX's P/E ratio is -32.23. In terms of profitability, CD3.AX's ROE is +0.13%, compared to GDG.AX's ROE of -0.05%. Regarding short-term risk, CD3.AX is less volatile compared to GDG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check GDG.AX's competition here
CD3.AX vs ETPMAG.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, ETPMAG.AX has a market cap of 1.6B. Regarding current trading prices, CD3.AX is priced at A$0.92, while ETPMAG.AX trades at A$99.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas ETPMAG.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to ETPMAG.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to ETPMAG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check ETPMAG.AX's competition here
CD3.AX vs GDX.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, GDX.AX has a market cap of 1.6B. Regarding current trading prices, CD3.AX is priced at A$0.92, while GDX.AX trades at A$143.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas GDX.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to GDX.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to GDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check GDX.AX's competition here
CD3.AX vs GLIN.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, GLIN.AX has a market cap of 1.5B. Regarding current trading prices, CD3.AX is priced at A$0.92, while GLIN.AX trades at A$31.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas GLIN.AX's P/E ratio is 16.28. In terms of profitability, CD3.AX's ROE is +0.13%, compared to GLIN.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to GLIN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check GLIN.AX's competition here
CD3.AX vs QAU.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, QAU.AX has a market cap of 1.5B. Regarding current trading prices, CD3.AX is priced at A$0.92, while QAU.AX trades at A$37.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas QAU.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to QAU.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to QAU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check QAU.AX's competition here
CD3.AX vs IAA.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IAA.AX has a market cap of 1.5B. Regarding current trading prices, CD3.AX is priced at A$0.92, while IAA.AX trades at A$163.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IAA.AX's P/E ratio is 18.48. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IAA.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to IAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IAA.AX's competition here
CD3.AX vs IEM.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IEM.AX has a market cap of 1.5B. Regarding current trading prices, CD3.AX is priced at A$0.92, while IEM.AX trades at A$87.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IEM.AX's P/E ratio is 16.99. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IEM.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to IEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IEM.AX's competition here
CD3.AX vs IWLD.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IWLD.AX has a market cap of 1.5B. Regarding current trading prices, CD3.AX is priced at A$0.92, while IWLD.AX trades at A$64.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IWLD.AX's P/E ratio is 24.32. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IWLD.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to IWLD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IWLD.AX's competition here
CD3.AX vs BKI.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, BKI.AX has a market cap of 1.4B. Regarding current trading prices, CD3.AX is priced at A$0.92, while BKI.AX trades at A$1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas BKI.AX's P/E ratio is 21.63. In terms of profitability, CD3.AX's ROE is +0.13%, compared to BKI.AX's ROE of +0.05%. Regarding short-term risk, CD3.AX is less volatile compared to BKI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check BKI.AX's competition here
CD3.AX vs VDGR.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VDGR.AX has a market cap of 1.4B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VDGR.AX trades at A$66.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VDGR.AX's P/E ratio is 21.95. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VDGR.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VDGR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VDGR.AX's competition here
CD3.AX vs AUI.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, AUI.AX has a market cap of 1.4B. Regarding current trading prices, CD3.AX is priced at A$0.92, while AUI.AX trades at A$10.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas AUI.AX's P/E ratio is 26.02. In terms of profitability, CD3.AX's ROE is +0.13%, compared to AUI.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is less volatile compared to AUI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check AUI.AX's competition here
CD3.AX vs VGB.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VGB.AX has a market cap of 1.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VGB.AX trades at A$45.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VGB.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VGB.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VGB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VGB.AX's competition here
CD3.AX vs CNI.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, CNI.AX has a market cap of 1.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while CNI.AX trades at A$1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas CNI.AX's P/E ratio is 11.04. In terms of profitability, CD3.AX's ROE is +0.13%, compared to CNI.AX's ROE of +0.08%. Regarding short-term risk, CD3.AX is less volatile compared to CNI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check CNI.AX's competition here
CD3.AX vs VESG.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VESG.AX has a market cap of 1.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VESG.AX trades at A$106.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VESG.AX's P/E ratio is 24.23. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VESG.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VESG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VESG.AX's competition here
CD3.AX vs BBUS.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, BBUS.AX has a market cap of 1.3B. Regarding current trading prices, CD3.AX is priced at A$0.92, while BBUS.AX trades at A$28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas BBUS.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to BBUS.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to BBUS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check BBUS.AX's competition here
CD3.AX vs MAF.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, MAF.AX has a market cap of 1.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while MAF.AX trades at A$7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas MAF.AX's P/E ratio is 117.00. In terms of profitability, CD3.AX's ROE is +0.13%, compared to MAF.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is less volatile compared to MAF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MAF.AX's competition here
CD3.AX vs ASIA.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, ASIA.AX has a market cap of 1.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while ASIA.AX trades at A$16.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas ASIA.AX's P/E ratio is 23.40. In terms of profitability, CD3.AX's ROE is +0.13%, compared to ASIA.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to ASIA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check ASIA.AX's competition here
CD3.AX vs BILL.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, BILL.AX has a market cap of 1.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while BILL.AX trades at A$100.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas BILL.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to BILL.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to BILL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check BILL.AX's competition here
CD3.AX vs ILB.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, ILB.AX has a market cap of 1.2B. Regarding current trading prices, CD3.AX is priced at A$0.92, while ILB.AX trades at A$125.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas ILB.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to ILB.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to ILB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check ILB.AX's competition here
CD3.AX vs FLOT.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, FLOT.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while FLOT.AX trades at A$24.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas FLOT.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to FLOT.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to FLOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check FLOT.AX's competition here
CD3.AX vs AGVT.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, AGVT.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while AGVT.AX trades at A$40.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas AGVT.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to AGVT.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to AGVT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check AGVT.AX's competition here
CD3.AX vs DUI.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, DUI.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while DUI.AX trades at A$5.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas DUI.AX's P/E ratio is 29.82. In terms of profitability, CD3.AX's ROE is +0.13%, compared to DUI.AX's ROE of +0.03%. Regarding short-term risk, CD3.AX is less volatile compared to DUI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check DUI.AX's competition here
CD3.AX vs FAIR.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, FAIR.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while FAIR.AX trades at A$18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas FAIR.AX's P/E ratio is 21.32. In terms of profitability, CD3.AX's ROE is +0.13%, compared to FAIR.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to FAIR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check FAIR.AX's competition here
CD3.AX vs VSO.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VSO.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while VSO.AX trades at A$73.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VSO.AX's P/E ratio is 20.13. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VSO.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to VSO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VSO.AX's competition here
CD3.AX vs QOZ.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, QOZ.AX has a market cap of 1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while QOZ.AX trades at A$19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas QOZ.AX's P/E ratio is 20.90. In terms of profitability, CD3.AX's ROE is +0.13%, compared to QOZ.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to QOZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check QOZ.AX's competition here
CD3.AX vs QUS.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, QUS.AX has a market cap of 1B. Regarding current trading prices, CD3.AX is priced at A$0.92, while QUS.AX trades at A$52.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas QUS.AX's P/E ratio is 22.99. In terms of profitability, CD3.AX's ROE is +0.13%, compared to QUS.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to QUS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check QUS.AX's competition here
CD3.AX vs VIF.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VIF.AX has a market cap of 993.5M. Regarding current trading prices, CD3.AX is priced at A$0.92, while VIF.AX trades at A$37.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VIF.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VIF.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VIF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VIF.AX's competition here
CD3.AX vs IEU.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IEU.AX has a market cap of 970.1M. Regarding current trading prices, CD3.AX is priced at A$0.92, while IEU.AX trades at A$100.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IEU.AX's P/E ratio is 18.44. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IEU.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to IEU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IEU.AX's competition here
CD3.AX vs RPL.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, RPL.AX has a market cap of 967.2M. Regarding current trading prices, CD3.AX is priced at A$0.92, while RPL.AX trades at A$2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas RPL.AX's P/E ratio is 7.74. In terms of profitability, CD3.AX's ROE is +0.13%, compared to RPL.AX's ROE of +0.15%. Regarding short-term risk, CD3.AX is less volatile compared to RPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check RPL.AX's competition here
CD3.AX vs CIN.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, CIN.AX has a market cap of 946.8M. Regarding current trading prices, CD3.AX is priced at A$0.92, while CIN.AX trades at A$35.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas CIN.AX's P/E ratio is 24.09. In terms of profitability, CD3.AX's ROE is +0.13%, compared to CIN.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is less volatile compared to CIN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check CIN.AX's competition here
CD3.AX vs MOAT.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, MOAT.AX has a market cap of 911.3M. Regarding current trading prices, CD3.AX is priced at A$0.92, while MOAT.AX trades at A$117.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas MOAT.AX's P/E ratio is 25.08. In terms of profitability, CD3.AX's ROE is +0.13%, compared to MOAT.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to MOAT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MOAT.AX's competition here
CD3.AX vs IHWL.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IHWL.AX has a market cap of 888.8M. Regarding current trading prices, CD3.AX is priced at A$0.92, while IHWL.AX trades at A$61.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IHWL.AX's P/E ratio is 25.00. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IHWL.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to IHWL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IHWL.AX's competition here
CD3.AX vs IJP.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IJP.AX has a market cap of 869.4M. Regarding current trading prices, CD3.AX is priced at A$0.92, while IJP.AX trades at A$123.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IJP.AX's P/E ratio is 17.96. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IJP.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to IJP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IJP.AX's competition here
CD3.AX vs VDBA.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VDBA.AX has a market cap of 865.9M. Regarding current trading prices, CD3.AX is priced at A$0.92, while VDBA.AX trades at A$59.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VDBA.AX's P/E ratio is 21.74. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VDBA.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to VDBA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VDBA.AX's competition here
CD3.AX vs MVA.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, MVA.AX has a market cap of 852M. Regarding current trading prices, CD3.AX is priced at A$0.92, while MVA.AX trades at A$22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas MVA.AX's P/E ratio is 12.68. In terms of profitability, CD3.AX's ROE is +0.13%, compared to MVA.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to MVA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MVA.AX's competition here
CD3.AX vs IJR.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IJR.AX has a market cap of 839.1M. Regarding current trading prices, CD3.AX is priced at A$0.92, while IJR.AX trades at A$186.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IJR.AX's P/E ratio is 17.34. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IJR.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to IJR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IJR.AX's competition here
CD3.AX vs VISM.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VISM.AX has a market cap of 816M. Regarding current trading prices, CD3.AX is priced at A$0.92, while VISM.AX trades at A$72.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VISM.AX's P/E ratio is 17.96. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VISM.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to VISM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VISM.AX's competition here
CD3.AX vs VACF.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VACF.AX has a market cap of 754M. Regarding current trading prices, CD3.AX is priced at A$0.92, while VACF.AX trades at A$50.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VACF.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VACF.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VACF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VACF.AX's competition here
CD3.AX vs DJW.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, DJW.AX has a market cap of 751.8M. Regarding current trading prices, CD3.AX is priced at A$0.92, while DJW.AX trades at A$2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas DJW.AX's P/E ratio is 20.43. In terms of profitability, CD3.AX's ROE is +0.13%, compared to DJW.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is less volatile compared to DJW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check DJW.AX's competition here
CD3.AX vs VAE.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VAE.AX has a market cap of 744.1M. Regarding current trading prices, CD3.AX is priced at A$0.92, while VAE.AX trades at A$99.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VAE.AX's P/E ratio is 16.31. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VAE.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to VAE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VAE.AX's competition here
CD3.AX vs ILC.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, ILC.AX has a market cap of 734M. Regarding current trading prices, CD3.AX is priced at A$0.92, while ILC.AX trades at A$35.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas ILC.AX's P/E ratio is 21.76. In terms of profitability, CD3.AX's ROE is +0.13%, compared to ILC.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to ILC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check ILC.AX's competition here
CD3.AX vs SFY.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, SFY.AX has a market cap of 719.5M. Regarding current trading prices, CD3.AX is priced at A$0.92, while SFY.AX trades at A$79.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas SFY.AX's P/E ratio is 21.66. In terms of profitability, CD3.AX's ROE is +0.13%, compared to SFY.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to SFY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check SFY.AX's competition here
CD3.AX vs ACDC.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, ACDC.AX has a market cap of 713.7M. Regarding current trading prices, CD3.AX is priced at A$0.92, while ACDC.AX trades at A$157.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas ACDC.AX's P/E ratio is 26.54. In terms of profitability, CD3.AX's ROE is +0.13%, compared to ACDC.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to ACDC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check ACDC.AX's competition here
CD3.AX vs REIT.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, REIT.AX has a market cap of 688.6M. Regarding current trading prices, CD3.AX is priced at A$0.92, while REIT.AX trades at A$16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas REIT.AX's P/E ratio is 22.14. In terms of profitability, CD3.AX's ROE is +0.13%, compared to REIT.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to REIT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check REIT.AX's competition here
CD3.AX vs IVE.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, IVE.AX has a market cap of 688.1M. Regarding current trading prices, CD3.AX is priced at A$0.92, while IVE.AX trades at A$143.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas IVE.AX's P/E ratio is 18.70. In terms of profitability, CD3.AX's ROE is +0.13%, compared to IVE.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to IVE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check IVE.AX's competition here
CD3.AX vs BHYB.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, BHYB.AX has a market cap of 663.4M. Regarding current trading prices, CD3.AX is priced at A$0.92, while BHYB.AX trades at A$9.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas BHYB.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is +0.13%, compared to BHYB.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to BHYB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check BHYB.AX's competition here
CD3.AX vs WXOZ.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, WXOZ.AX has a market cap of 656.5M. Regarding current trading prices, CD3.AX is priced at A$0.92, while WXOZ.AX trades at A$48.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas WXOZ.AX's P/E ratio is 23.72. In terms of profitability, CD3.AX's ROE is +0.13%, compared to WXOZ.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to WXOZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check WXOZ.AX's competition here
CD3.AX vs HM1.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, HM1.AX has a market cap of 648M. Regarding current trading prices, CD3.AX is priced at A$0.92, while HM1.AX trades at A$2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas HM1.AX's P/E ratio is 35.38. In terms of profitability, CD3.AX's ROE is +0.13%, compared to HM1.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is less volatile compared to HM1.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check HM1.AX's competition here
CD3.AX vs SEMI.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, SEMI.AX has a market cap of 633.5M. Regarding current trading prices, CD3.AX is priced at A$0.92, while SEMI.AX trades at A$28.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas SEMI.AX's P/E ratio is 37.85. In terms of profitability, CD3.AX's ROE is +0.13%, compared to SEMI.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to SEMI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check SEMI.AX's competition here
CD3.AX vs MVR.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, MVR.AX has a market cap of 627.4M. Regarding current trading prices, CD3.AX is priced at A$0.92, while MVR.AX trades at A$49.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas MVR.AX's P/E ratio is 11.51. In terms of profitability, CD3.AX's ROE is +0.13%, compared to MVR.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to MVR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MVR.AX's competition here
CD3.AX vs YMAX.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, YMAX.AX has a market cap of 614.8M. Regarding current trading prices, CD3.AX is priced at A$0.92, while YMAX.AX trades at A$7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas YMAX.AX's P/E ratio is 22.18. In terms of profitability, CD3.AX's ROE is +0.13%, compared to YMAX.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to YMAX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check YMAX.AX's competition here
CD3.AX vs EX20.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, EX20.AX has a market cap of 613.2M. Regarding current trading prices, CD3.AX is priced at A$0.92, while EX20.AX trades at A$22.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas EX20.AX's P/E ratio is 21.36. In terms of profitability, CD3.AX's ROE is +0.13%, compared to EX20.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to EX20.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check EX20.AX's competition here
CD3.AX vs SYI.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, SYI.AX has a market cap of 612.7M. Regarding current trading prices, CD3.AX is priced at A$0.92, while SYI.AX trades at A$31.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas SYI.AX's P/E ratio is 19.84. In terms of profitability, CD3.AX's ROE is +0.13%, compared to SYI.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to SYI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check SYI.AX's competition here
CD3.AX vs L1G.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, L1G.AX has a market cap of 608.5M. Regarding current trading prices, CD3.AX is priced at A$0.92, while L1G.AX trades at A$1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas L1G.AX's P/E ratio is 109.50. In terms of profitability, CD3.AX's ROE is +0.13%, compared to L1G.AX's ROE of +0.59%. Regarding short-term risk, CD3.AX is less volatile compared to L1G.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check L1G.AX's competition here
CD3.AX vs MIR.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, MIR.AX has a market cap of 588.7M. Regarding current trading prices, CD3.AX is priced at A$0.92, while MIR.AX trades at A$2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas MIR.AX's P/E ratio is 43.83. In terms of profitability, CD3.AX's ROE is +0.13%, compared to MIR.AX's ROE of +0.01%. Regarding short-term risk, CD3.AX is less volatile compared to MIR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MIR.AX's competition here
CD3.AX vs OPH.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, OPH.AX has a market cap of 576.5M. Regarding current trading prices, CD3.AX is priced at A$0.92, while OPH.AX trades at A$2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas OPH.AX's P/E ratio is 5.51. In terms of profitability, CD3.AX's ROE is +0.13%, compared to OPH.AX's ROE of N/A. Regarding short-term risk, CD3.AX is less volatile compared to OPH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check OPH.AX's competition here
CD3.AX vs VEQ.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, VEQ.AX has a market cap of 572.2M. Regarding current trading prices, CD3.AX is priced at A$0.92, while VEQ.AX trades at A$88.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas VEQ.AX's P/E ratio is 18.72. In terms of profitability, CD3.AX's ROE is +0.13%, compared to VEQ.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to VEQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check VEQ.AX's competition here
CD3.AX vs AEF.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, AEF.AX has a market cap of 566.9M. Regarding current trading prices, CD3.AX is priced at A$0.92, while AEF.AX trades at A$4.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas AEF.AX's P/E ratio is 23.71. In terms of profitability, CD3.AX's ROE is +0.13%, compared to AEF.AX's ROE of +0.55%. Regarding short-term risk, CD3.AX is less volatile compared to AEF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check AEF.AX's competition here
CD3.AX vs FGX.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, FGX.AX has a market cap of 560.9M. Regarding current trading prices, CD3.AX is priced at A$0.92, while FGX.AX trades at A$1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas FGX.AX's P/E ratio is 10.50. In terms of profitability, CD3.AX's ROE is +0.13%, compared to FGX.AX's ROE of +0.09%. Regarding short-term risk, CD3.AX is less volatile compared to FGX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check FGX.AX's competition here
CD3.AX vs EQT.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, EQT.AX has a market cap of 533.4M. Regarding current trading prices, CD3.AX is priced at A$0.92, while EQT.AX trades at A$19.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas EQT.AX's P/E ratio is 12.85. In terms of profitability, CD3.AX's ROE is +0.13%, compared to EQT.AX's ROE of +0.10%. Regarding short-term risk, CD3.AX is less volatile compared to EQT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check EQT.AX's competition here
CD3.AX vs QRE.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, QRE.AX has a market cap of 532.3M. Regarding current trading prices, CD3.AX is priced at A$0.92, while QRE.AX trades at A$10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas QRE.AX's P/E ratio is 20.37. In terms of profitability, CD3.AX's ROE is +0.13%, compared to QRE.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to QRE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check QRE.AX's competition here
CD3.AX vs GEAR.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, GEAR.AX has a market cap of 527.4M. Regarding current trading prices, CD3.AX is priced at A$0.92, while GEAR.AX trades at A$37.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas GEAR.AX's P/E ratio is 21.53. In terms of profitability, CD3.AX's ROE is +0.13%, compared to GEAR.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is less volatile compared to GEAR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check GEAR.AX's competition here
CD3.AX vs PMC.AX Comparison April 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 65.9M. In comparison, PMC.AX has a market cap of 523.5M. Regarding current trading prices, CD3.AX is priced at A$0.92, while PMC.AX trades at A$1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of 3.98, whereas PMC.AX's P/E ratio is 58.83. In terms of profitability, CD3.AX's ROE is +0.13%, compared to PMC.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is less volatile compared to PMC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check PMC.AX's competition here